The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: LPS antibody-based anti-bacterials. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

LPS antibody-based anti-bacterials is a key innovation area in the pharmaceutical industry

A major component of gram-negative bacteria's outer membrane is lipopolysaccharide (LPS). LPS elicits an overwhelming immune response during infection, which can result in life-threatening sepsis or septic shock. LPS antibodies (monoclonal or polyclonal) can be used directly as immunotherapeutic agents for gram-negative sepsis or endotoxaemia, or as probes for diagnosing and investigating gram-negative bacterial infections. Anti-LPS antibodies have provided the basis for traditional and more recent serological studies of major bacterial infections.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 90+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of LPS antibody-based anti-bacterials.

Key players in LPS antibody-based anti-bacterials – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to LPS antibody-based anti-bacterials

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
GSK 1839 Unlock Company Profile
Pfizer 1089 Unlock Company Profile
Merck & Co 415 Unlock Company Profile
Zoetis 269 Unlock Company Profile
Sanofi 260 Unlock Company Profile
C. H. Boehringer Sohn 185 Unlock Company Profile
SK Chemicals 150 Unlock Company Profile
Selecta Biosciences 105 Unlock Company Profile
Nestle 97 Unlock Company Profile
Biological E 76 Unlock Company Profile
Molecular Templates 67 Unlock Company Profile
National Research Council of Canada 59 Unlock Company Profile
Max-Planck-Gesellschaft 55 Unlock Company Profile
Hilleman Laboratories Pvt 50 Unlock Company Profile
Children's Medical Center 48 Unlock Company Profile
Novartis 43 Unlock Company Profile
Bharat Biotech 40 Unlock Company Profile
Intervet 40 Unlock Company Profile
IRCCS Policlinico San Donato 34 Unlock Company Profile
Johnson & Johnson 33 Unlock Company Profile
U.S. Department of Defense 33 Unlock Company Profile
Inventprise 32 Unlock Company Profile
Fina Biosolutions 32 Unlock Company Profile
Vaxcyte 31 Unlock Company Profile
TheVax Genetics Vaccine 31 Unlock Company Profile
Mariposa Health 28 Unlock Company Profile
Calliditas Therapeutics 26 Unlock Company Profile
Scandinavian Biopharma Holding 25 Unlock Company Profile
Kerry Group 23 Unlock Company Profile
Genocea Biosciences 22 Unlock Company Profile
Matrivax 21 Unlock Company Profile
Aeterna Zentaris 21 Unlock Company Profile
Qu Biologics 20 Unlock Company Profile
Max Planck Gesellschaft zur Forderung der Wissenschaften 20 Unlock Company Profile
Immunology Laboratories 20 Unlock Company Profile
VaxNewMO 17 Unlock Company Profile
Longhorn Vaccines and Diagnostics 17 Unlock Company Profile
Meiji Holdings 16 Unlock Company Profile
Panacea Biotec 16 Unlock Company Profile
US Department of Health and Human Services 16 Unlock Company Profile
Centre National de la Recherche Scientifique 15 Unlock Company Profile
Hillhouse Capital Group 15 Unlock Company Profile
Vaxdyn 14 Unlock Company Profile
Inmunova 14 Unlock Company Profile
Vaxil Bio 14 Unlock Company Profile
Aileens Pharma 14 Unlock Company Profile
Minervax 14 Unlock Company Profile
Mico Bio 14 Unlock Company Profile
PAH USA 15 13 Unlock Company Profile
Vakcina Kft 13 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is the leading patent filer in LPS antibody-based anti-bacterials. GSK develops, manufactures and commercialises pharmaceuticals, vaccines, and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, and for diseases within therapy areas such as respiratory, cancer, immuno-inflammation, infectious diseases, central nervous system (CNS), metabolic, cardiovascular, , and dermatology. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles, and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians, and other groups worldwide.

Other key patent filers in LPS antibody-based anti-bacterials space are Pfizer and Merck.

In terms of application diversity, Andalusian Health Service is the top company, followed by Vaxdyn SL and TheVax Genetics Vaccine. By means of geographic reach, Selecta Biosciences holds the top position. Whilst IRCCS Policlinico San Donato and Fina Biosolutions are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.